Literature DB >> 8215659

Mid-term results after bidirectional cavopulmonary shunts.

J A Hawkins1, R E Shaddy, R W Day, J E Sturtevant, G S Orsmond, E C McGough.   

Abstract

Despite the increasing use of the bidirectional cavopulmonary shunt, little is known about the late results, the duration of palliation, and the frequency with which this procedure allows later successful conversion to a Fontan type of procedure. We reviewed our experience (1984 to 1992) in 38 consecutive children, ages 4 months to 16 years (mean, 4.0 years), who underwent a bidirectional cavopulmonary shunt procedure. All had a single functional ventricle and represented high risks for the performance of a Fontan procedure based on anatomic and hemodynamic criteria. The oxygen saturation in these patients improved from a preoperative value of 75% +/- 7% to 82% +/- 7% (p < 0.05) at late cardiac catheterization by a mean of 24 months after operation. The actuarial survival, including early deaths and that associated with all secondary procedures, was 86% at 1 year and 81% at 6 years. Early deaths occurred in 5.3% (2/38) and late deaths in 11% (4/36). Late follow-up ranged from 5 to 90 months (mean, 37 months). Conversion to a Fontan or fenestrated Fontan procedure was accomplished in 21 early survivors (21/36; 58%) by a mean of 26 months after the bidirectional cavopulmonary shunt procedure, with one operative and no late deaths (1/21; 4.8%). Three additional patients have undergone late reoperation, including 2 requiring cardiac transplantation and 1 undergoing the late creation of an axillary artery-to-vein fistula for the treatment of cyanosis. The midterm survival after a bidirectional cavopulmonary shunt procedure appears to be excellent, and it serves as a good staging procedure for patients who represent high risks for a Fontan procedure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8215659     DOI: 10.1016/0003-4975(93)90340-n

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  [The role of bidirectional cavopulmonary shunt on selection of Fontan patients].

Authors:  Y Cho; T Katogi; R Aeba; Y Inoue; K Moro; T Omoto; Y Nakao; S Kawada
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-12

2.  Elevated Pulmonary Artery Pressure, Not Pulmonary Vascular Resistance, is an Independent Predictor of Short-Term Morbidity Following Bidirectional Cavopulmonary Connection.

Authors:  Susanna Tran; Patrick M Sullivan; John Cleveland; S Ram Kumar; Cheryl Takao
Journal:  Pediatr Cardiol       Date:  2018-06-14       Impact factor: 1.655

3.  Bidirectional superior cavopulmonary anastomosis: how young is too young?

Authors:  Z Slavik; R K Lamb; S A Webber; A M Devlin; B R Keeton; J L Monro; A P Salmon
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

4.  The role of a staged approach for high-risk Fontan candidates.

Authors:  K Morita; H Kurosawa; A Mizuno; Y Sakamoto; K Tanaka; Y Uno; N Kawada; M Hanai; K Sugiyama
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-10

5.  Risk factors for failed staged palliation after bidirectional Glenn in infants who have undergone stage one palliation.

Authors:  Kevin G Friedman; Joshua W Salvin; David Wypij; Yared Gurmu; Emile A Bacha; David W Brown; Peter C Laussen; Mark A Scheurer
Journal:  Eur J Cardiothorac Surg       Date:  2011-03-05       Impact factor: 4.191

6.  Staged Fontan procedure for mitral atresia associated with severe tricuspid regurgitation, pulmonary hypertension, and pulmonary artery distortion.

Authors:  Yoko Matsumura; Hiromi Kurosawa; Kiyozo Morita; Koji Nomura; Shogo Shimizu; Akira Tatara
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-04

7.  Factors determining early outcomes after the bidirectional superior cavopulmonary anastomosis.

Authors:  Sachin Talwar; Tsering Sandup; Saurabh Gupta; Sivasubramanian Ramakrishnan; Shyam Sunder Kothari; Anita Saxena; Rajnish Juneja; Shiv Kumar Choudhary; Balram Airan
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2017-08-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.